{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:57:15Z","timestamp":1789498635809,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,4,11]],"date-time":"2015-04-11T00:00:00Z","timestamp":1428710400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1007\/s40261-015-0287-5","type":"journal-article","created":{"date-parts":[[2015,4,10]],"date-time":"2015-04-10T23:28:14Z","timestamp":1428708494000},"page":"327-333","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Tenofovir-Associated Nephrotoxicity in Children with Perinatally-Acquired HIV Infection: A Single-Centre Cohort Study"],"prefix":"10.1007","volume":"35","author":[{"given":"Yinru","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermione","family":"Lyall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,4,11]]},"reference":[{"key":"287_CR1","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1001\/archinte.165.4.416","volume":"165","author":"A D\u2019Arminio Monforte","year":"2005","unstructured":"D\u2019Arminio Monforte A, Sabin CA, Philips A, et al. The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. Arch Intern Med. 2005;165:416\u201323.","journal-title":"Arch Intern Med"},{"key":"287_CR2","unstructured":"World Health Organization. Data and statistics. Available at: www.who.int . Accessed Sept 2014."},{"key":"287_CR3","unstructured":"World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. 2013. Available at: http:\/\/www.who.int\/hiv\/pub\/guidelines\/arv2013\/en\/ . Accessed 28 Feb 2015."},{"issue":"7","key":"287_CR4","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1086\/378068","volume":"37","author":"JE Gallant","year":"2003","unstructured":"Gallant JE, Deresinski S. Tenofovir disoproxil fumarate. Clin Infect Dis. 2003;37(7):944\u201350.","journal-title":"Clin Infect Dis."},{"issue":"3","key":"287_CR5","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1517\/17425255.2.3.459","volume":"2","author":"PA Pham","year":"2006","unstructured":"Pham PA, Gallant JE. Tenofovir disoproxil fumarate for the treatment of HIV infection. Expert Opin Drug Metab Toxicol. 2006;2(3):459\u201369.","journal-title":"Expert Opin Drug Metab Toxicol."},{"issue":"6","key":"287_CR6","doi-asserted-by":"crossref","first-page":"e846","DOI":"10.1542\/peds.2005-0975","volume":"116","author":"R Hazra","year":"2005","unstructured":"Hazra R, Gafni R, Malderelli F, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection. Pediatrics. 2005;116(6):e846\u201354.","journal-title":"Pediatrics."},{"issue":"5","key":"287_CR7","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1128\/AAC.01064-08","volume":"53","author":"A Pruvost","year":"2009","unstructured":"Pruvost A, Negredo E, Theodora F, et al. Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir. Antimicrob Agents Chemother. 2009;53(5):1937\u201343.","journal-title":"Antimicrob Agents Chemother."},{"key":"287_CR8","unstructured":"Paediatric European Network for Treatment of AIDS (PENTA-ID). PENTA guidelines for treatment of paediatric HIV-1 infection 2015: optimising health in preparation for adult life. Available at: http:\/\/penta-id.org\/hiv\/penta-trials-treatmentguidelines.html . Accessed Feb 2015."},{"key":"287_CR9","unstructured":"AIDSinfo. Guidelines for the use of antiretroviral agents in pediatric HIV infection. 2013. http:\/\/aidsinfo.nih.gov\/guidelines\/html\/2\/pediatric-treatmentguidelines\/0 . Accessed 7 Mar 2015."},{"key":"287_CR10","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/00126334-200403010-00007","volume":"35","author":"H Peyriere","year":"2004","unstructured":"Peyriere H, Peynes J, Rouanet I, et al. Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr. 2004;35:269\u201373.","journal-title":"J Acquir Immune Defic Syndr."},{"issue":"5","key":"287_CR11","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1086\/655681","volume":"51","author":"RD Cooper","year":"2010","unstructured":"Cooper RD, Wiebe N, Smith N, et al. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis. 2010;51(5):496\u2013505.","journal-title":"Clin Infect Dis."},{"key":"287_CR12","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/QAD.0b013e3283333680","volume":"24","author":"A Judd","year":"2010","unstructured":"Judd A, Boyd KL, Stohr W, et al. Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1 infected children on antiretroviral therapy: a nested case-control study. AIDS. 2010;24:525\u201334.","journal-title":"AIDS."},{"key":"287_CR13","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/INF.0b013e31818c8d2c","volume":"28","author":"A Riordan","year":"2009","unstructured":"Riordan A, Judd A, Boyd K, et al. Tenofovir use in human immunodeficiency virus-1-infected children in the United Kingdom and Ireland. Pediatr Infect Dis J. 2009;28:204\u20139.","journal-title":"Pediatr Infect Dis J."},{"key":"287_CR14","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s00467-012-2269-7","volume":"28","author":"A Hall","year":"2013","unstructured":"Hall A. Update on tenofovir toxicity in the kidney. Pediatr Nephrol. 2013;28:1011\u201323.","journal-title":"Pediatr Nephrol."},{"key":"287_CR15","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/INF.0b013e31824bf239","volume":"31","author":"MD Della Negra","year":"2012","unstructured":"Della Negra MD, Carvalho A, Aquino M, et al. A randomized study of tenofovir disoproxil fumarate in treatment-experienced HIV-1 infected adolescents. Pediatr Infect Dis J. 2012;31:469\u201373.","journal-title":"Pediatr Infect Dis J."},{"issue":"7","key":"287_CR16","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1097\/QAD.0b013e328351f68f","volume":"26","author":"R Scherzer","year":"2012","unstructured":"Scherzer R, Estrella M, Li Y, et al. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS. 2012;26(7):867\u201375.","journal-title":"AIDS."},{"key":"287_CR17","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/INF.0b013e31827f4eff","volume":"32","author":"M Purswani","year":"2013","unstructured":"Purswani M, Patel K, Kopp JB, et al. Tenofovir treatment duration predicts proteinuria in a multi-ethnic United States cohort of children and adolescents with perinatal HIV-1 infection. Pediatr Infect Dis J. 2013;32:495\u2013500.","journal-title":"Pediatr Infect Dis J."},{"issue":"7","key":"287_CR18","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1097\/QAD.0b013e32833202e2","volume":"24","author":"S Rodriguez-Novoa","year":"2010","unstructured":"Rodriguez-Novoa S, Labarga P, D\u2019avolio A, et al. Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. AIDS. 2010;24(7):1064\u20136.","journal-title":"AIDS."},{"issue":"7","key":"287_CR19","doi-asserted-by":"crossref","first-page":"e22661","DOI":"10.1371\/journal.pone.0022661","volume":"6","author":"T Nishijima","year":"2011","unstructured":"Nishijima T, Komatsu H, Gatanaga H, et al. Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients. PLoS One. 2011;6(7):e22661.","journal-title":"PLoS One."},{"key":"287_CR20","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1086\/524061","volume":"197","author":"M Goicoechea","year":"2008","unstructured":"Goicoechea M, Liu S, Best B, et al. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis. 2008;197:102\u20138.","journal-title":"J Infect Dis."},{"key":"287_CR21","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1471-2334-12-18","volume":"12","author":"G Pontrelli","year":"2012","unstructured":"Pontrelli G, Cotugno N, Amodio D, et al. Renal function in HIV-infected children and adolescent treated with tenofovir disoproxil fumarate and protease inhibitors. BMC Infect Dis. 2012;12:18.","journal-title":"BMC Infect Dis."},{"issue":"10","key":"287_CR22","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.2217\/pgs.09.115","volume":"10","author":"S Rodriguez-Novoa","year":"2009","unstructured":"Rodriguez-Novoa S, Labarga P, Soriano V. Pharmacogenetics of tenofovir treatment. Pharmacogenomics. 2009;10(10):1675\u201385.","journal-title":"Pharmacogenomics."},{"key":"287_CR23","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1007\/s00467-006-0109-3","volume":"21","author":"S Hussain","year":"2006","unstructured":"Hussain S, Khayat A, Tolaymat A, Rathore MH. Nephrotoxicity in a child with perinatal HIV on tenofovir, didanosine and lopinavir\/ritonavir. Pediatr Nephrol. 2006;21:1034\u20136.","journal-title":"Pediatr Nephrol."},{"key":"287_CR24","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1468-1293.2007.00497.x","volume":"8","author":"S Hawkins","year":"2007","unstructured":"Hawkins S, Ball C. Adverse events experienced by 3 children taking tenofovir and didanosine in combination. HIV Med. 2007;8:411.","journal-title":"HIV Med."},{"key":"287_CR25","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1086\/376991","volume":"37","author":"JN Blanchard","year":"2003","unstructured":"Blanchard JN, Wohlfeiler M, Canas A, et al. Pancreatitis with didanosine and tenofovir disoproxil fumarate. Clin Infect Dis. 2003;37:e57\u201362.","journal-title":"Clin Infect Dis."},{"key":"287_CR26","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1097\/01.aids.0000194136.73876.9c","volume":"19","author":"U Karrer","year":"2005","unstructured":"Karrer U, Ledergerber B, Furrer H, et al. Dose-dependent influence of didanosine on immune recovery in HIV infected patients treated with tenofovir. AIDS. 2005;19:1987\u201394.","journal-title":"AIDS."},{"issue":"3","key":"287_CR27","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/00002030-200402200-00012","volume":"18","author":"E Negredo","year":"2004","unstructured":"Negredo E, Molto J, Burger D, et al. Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load. AIDS. 2004;18(3):459\u201363.","journal-title":"AIDS."},{"issue":"1","key":"287_CR28","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.antiviral.2012.07.009","volume":"96","author":"A Bonjoch","year":"2012","unstructured":"Bonjoch A, Echeverria P, Perez-Alvarez N, et al. High rate of reversibility of renal damage in a cohort of HIV-infected patients receiving tenofovir-containing antiretroviral therapy. Antiviral Res. 2012;96(1):65\u20139.","journal-title":"Antiviral Res."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-015-0287-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-015-0287-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-015-0287-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T19:28:54Z","timestamp":1559503734000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-015-0287-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,11]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["287"],"URL":"https:\/\/doi.org\/10.1007\/s40261-015-0287-5","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,11]]}}}